Article by Kevin McDonald, Capital News
As the federal government’s spring goal for introducing legalized cannabis legislation grows nearer, interested parties continue to look to the country’s current medical access system for the drug to light the way.
On March 9th, medical cannabis producer Aurora Cannabis Inc. announced it would be introducing new disclosure processes for test results. The change is intended to make it easier for patients to access quality control test results for products sold by Aurora, but produced by a third party. The move also comes in light of voluntary recalls that Aurora, along with cannabis producer OrganiGram Inc., announced last December for products sold by Aurora, but made by OrganiGram.
Advocates for recreational cannabis see steps like these as a move in the right direction. For Dr. Craig Jones of NORML Canada (National Organization for the Reform of Marijuana Laws in Canada), the main concern in legalization is setting “stringent regulations to ensure the safety and purity of commercial products and liberty of access to persons who have reached the age of majority.”
However, for current medical cannabis users like Lucas Thorne, the main concern is making sure the new recreational cannabis market does not impede on the existing medical access system.
Thorne has been using medical cannabis for four years to treat symptoms of his Crohn’s Disease.
“Now that I’ve got everything set up between my specialty marijuana clinic in Sudbury that provided me with the Green Card and their growers in B.C., it only takes two to three days for my medicine to arrive after ordering it.”